AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
Public ClinicalTrials.gov record NCT04096326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
Study identification
- NCT ID
- NCT04096326
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 198 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2019
- Primary completion
- Sep 8, 2020
- Completion
- Sep 8, 2020
- Last update posted
- Jul 27, 2023
2019 – 2020
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Center for Dermatology Clinical Research /ID# 237798 | Fremont | California | 94538 | — |
| Ava T. Shamban MD - Santa Monica. /ID# 235353 | Santa Monica | California | 90404-2208 | — |
| Skin and Cancer Associates, LLP /ID# 236231 | Miami | Florida | 33137-3254 | — |
| Laser and Skin Surgery Center of Indiana /ID# 236588 | Indianapolis | Indiana | 46260-2386 | — |
| Wilmington Dermatology Center /ID# 237055 | Wilmington | North Carolina | 28403 | — |
| Kgl, Llc /Id# 234798 | Newtown Square | Pennsylvania | 19073-2228 | — |
| DermResearch Inc. /ID# 234483 | Austin | Texas | 78759 | — |
| Austin Institute for Clinical Research at SBA Dermatology /ID# 236646 | Houston | Texas | 77056-4129 | — |
| Austin Institute for Clinical Research /ID# 237135 | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04096326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2023 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04096326 live on ClinicalTrials.gov.